M. Miyara, D. Sterlin, F. Anna, S. Marot, A. Mathian, Mourad Atif, P. Quentric, A. Mohr, Laetitia Claër, C. Parizot, K. Dorgham, H. Yssel, T. Chazal, J. Fadlallah, J. Haroche, Neila Benameur, D. Boutolleau, S. Burrel, S. Mudumba, R. Hockett, C. Gunn, P. Charneau, V. Calvez, A. Marcellin, Z. Amoura, G. Gorochov
medRxiv, 2020
It is currently unknown whether acquired immunity to common alpha- and beta-coronaviruses provides cross-protection against SARS-CoV-2. In this study, we found that certain patient sera and intravenous immunoglobulins (IVIG) collected prior to the COVID-19 outbreak were cross-reactive to SARS-CoV-2 full-length Spike, S2 domain, and nucleoprotein. However, their presence did not translate into neutralizing activity against SARS-CoV-2 in vitro. Importantly, we detected serum IgG reactivity to common coronaviruses in the early sera of patients with severe COVID-19 before the appearance of anti-SARS-CoV-2 antibodies. Collectively, the results of our study indicate that pre-existing immunity to common coronaviruses does not confer cross-protection against SARS-CoV-2 in vivo.
Cited by 8 publications.
Field of study: Medicine